The Travelers Companies, Inc. · TRV · FY2024 Q3 · Calendar Q4 2024
Travelers posts record Q3 underwriting results as Corvus expands strategic focus
The supplied analysis supports a constructive near-term operating picture for Travelers: strong pricing, risk selection, underwriting profitability, investment income, and cash generation were paired with maintained guidance. The thesis is tempered by catastrophe exposure, uncertainty about pricing durability, and Corvus integration costs.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about TRV FY2024 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the current analysis describes stronger underwriting performance, a lower underlying combined ratio, higher investment income and cash flow, and a clearer role for Corvus in cyber and management-liability growth. It also introduces renewed focus on pricing durability, catastrophe exposure, and capital allocation.
Guidance delta
Management guidance sentiment was maintained; the supplied analysis does not identify a quantified guidance change.
Key takeaways
- Management described record third-quarter performance across its major segments.
- The supplied analysis highlights an 85.6% underlying combined ratio and 73% growth in underlying underwriting income.
- Investment income rose 16%, while operating cash flow reached $3.9 billion.
- Management plans to use Corvus capabilities to expand cyber and management-liability offerings.
- Catastrophe exposure, pricing durability, and integration costs remain key issues to monitor.
Management priorities
- Maintain disciplined pricing and risk selection.
- Invest in talent, technology, and Corvus integration.
- Adjust deductibles and eligibility in catastrophe-exposed states.
- Expand cyber insurance capabilities using Corvus assets.
- Balance share repurchases and dividends with business investment.
Follow TRV with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 24, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Mizuho | Neutral | Neutral | Maintain | Oct 20, 2026 |
| Keefe, Bruyette & Woods | Market Perform | Market Perform | Maintain | Oct 20, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Oct 20, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Oct 20, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Oct 19, 2026 |
| Truist Securities | Buy | Buy | Maintain | Oct 19, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Oct 19, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Oct 7, 2026 |
| Roth Capital | Buy | Buy | Maintain | Jul 21, 2026 |
| Morgan Stanley | Underweight | Underweight | Maintain | Jul 21, 2026 |
| Barclays | Underweight | Underweight | Maintain | Jul 21, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 20, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Jul 20, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 15, 2026 |
| TD Cowen | Sell | Hold | Downgrade | Jul 13, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 8, 2026 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Jul 6, 2026 |
| HSBC | Hold | Hold | Maintain | Jul 6, 2026 |
| Jefferies | Hold | Hold | Maintain | Apr 11, 2025 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Jan 23, 2025 |
| Goldman Sachs | Buy | Sell | Upgrade | Jan 8, 2025 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Nov 21, 2024 |
| Roth MKM | Buy | Buy | Maintain | Oct 21, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Aug 7, 2024 |
| William Blair | Market Perform | Outperform | Downgrade | Jun 28, 2024 |
| Oppenheimer | Perform | Perform | Maintain | Apr 5, 2024 |
| CFRA | Buy | Hold | Upgrade | Apr 19, 2023 |
| MKM Partners | Buy | Buy | Maintain | Jan 25, 2023 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Jun 23, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | Apr 1, 2021 |
| Buckingham Research | Neutral | Neutral | Maintain | Jan 22, 2020 |
| Buckingham | Neutral | Neutral | Maintain | Jan 22, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Sep 18, 2019 |
| Keefe Bruyette & Woods | Market Perform | Outperform | Downgrade | Jun 6, 2019 |
| B. Riley Securities | Neutral | Neutral | Maintain | Aug 7, 2018 |
| B. Riley FBR | Neutral | Neutral | Maintain | Aug 7, 2018 |
| Argus | Hold | Buy | Downgrade | May 5, 2018 |
| Argus Research | Buy | Buy | Maintain | Apr 26, 2018 |
| Atlantic Equities | Neutral | Underweight | Upgrade | Jan 26, 2018 |
| FBR Capital | Market Perform | Outperform | Downgrade | Feb 13, 2017 |
| Sandler O'Neill | Hold | Buy | Downgrade | Jul 28, 2014 |
| Guggenheim | Buy | Neutral | Upgrade | May 12, 2014 |
| Drexel Hamilton | Hold | Buy | Downgrade | Apr 24, 2013 |
| Sterne Agee | Neutral | Neutral | Maintain | Apr 20, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $398.28. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| BMO Capital | Analyst unavailable | $388 | $392.92 | -2.6% | Oct 20, 2026 |
| Mizuho Securities | Yaron Kinar | $371 | $385.45 | -6.8% | Oct 20, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $378 | $360.64 | -5.1% | Oct 7, 2026 |
| BMO Capital | Analyst unavailable | $379 | $368.5 | -4.8% | Jul 21, 2026 |
| Goldman Sachs | Alex Scott | $350 | $368.66 | -12.1% | Jul 20, 2026 |
| Truist Financial | Mark Hughes | $425 | $366.87 | +6.7% | Jul 20, 2026 |
| Raymond James | Gregory Peters | $430 | $368.98 | +8.0% | Jul 20, 2026 |
| Raymond James | Analyst unavailable | $307 | $368.98 | -22.9% | Jul 20, 2026 |
| Morgan Stanley | Analyst unavailable | $290 | $336.83 | -27.2% | Jul 15, 2026 |
| Piper Sandler | Paul Newsome | $340 | $339.42 | -14.6% | Jul 13, 2026 |
| Truist Financial | Mark Hughes | $395 | $337.48 | -0.8% | Jul 10, 2026 |
| Evercore ISI | Analyst unavailable | $329 | $337.48 | -17.4% | Jul 10, 2026 |
| Barclays | Alex Scott | $295 | $303.9 | -25.9% | Jun 12, 2026 |
| Seaport Global | Analyst unavailable | $322 | $306.46 | -19.2% | May 26, 2026 |
| BMO Capital | Analyst unavailable | $314 | $305.76 | -21.2% | Apr 20, 2026 |
| Goldman Sachs | Robert Cox | $304 | $283.19 | -23.7% | Jan 7, 2026 |
| Evercore ISI | Analyst unavailable | $317 | $284.98 | -20.4% | Jan 7, 2026 |
| Mizuho Securities | Yaron Kinar | $317 | $290.64 | -20.4% | Dec 15, 2025 |
| Barclays | Analyst unavailable | $313 | $284.97 | -21.4% | Oct 8, 2025 |
| Wells Fargo | Elyse Greenspan | $264 | $255.99 | -33.7% | Jul 10, 2025 |
| Morgan Stanley | Bob Huang | $269 | $274.54 | -32.5% | May 19, 2025 |
| Piper Sandler | Paul Newsome | $310 | $241.51 | -22.2% | Jan 24, 2025 |
| BMO Capital | Michael Zaremski | $270 | $259.7 | -32.2% | Oct 22, 2024 |
| JMP Securities | Meyer Shields | $273 | $259.7 | -31.5% | Oct 21, 2024 |
| Roth Capital | Harry Fong | $300 | $265.45 | -24.7% | Oct 21, 2024 |
| Wells Fargo | Elyse Greenspan | $256 | $265.45 | -35.7% | Oct 21, 2024 |
| Deutsche Bank | Cave Montazeri | $277 | $264.82 | -30.5% | Oct 18, 2024 |
| RBC Capital | Mark Dwelle | $273 | $264.82 | -31.5% | Oct 18, 2024 |
| Barclays | Alex Scott | $286 | $231.42 | -28.2% | Sep 4, 2024 |
| Piper Sandler | Paul Newsome | $207 | $203.48 | -48.0% | Jul 22, 2024 |
| Goldman Sachs | Alex Scott | $196 | $203.48 | -50.8% | Jul 22, 2024 |
| CFRA | Cathy Seifert | $225 | $203.48 | -43.5% | Jul 19, 2024 |
| Evercore ISI | David Motemaden | $236 | $203.48 | -40.7% | Jul 19, 2024 |
| Morgan Stanley | Bob Huang | $210 | $203.48 | -47.3% | Jul 19, 2024 |
| BMO Capital | Michael Zaremski | $240 | $203.48 | -39.7% | Jul 19, 2024 |
| J.P. Morgan | Jimmy Bhullar | $242 | $220.6 | -39.2% | Jul 19, 2024 |
| J.P. Morgan | Stephen Tusa | $95 | $213.07 | -76.1% | Jul 15, 2024 |
| RBC Capital | Mark Dwelle | $225 | $206.58 | -43.5% | Apr 18, 2024 |
| Goldman Sachs | Alex Scott | $202 | $206.58 | -49.3% | Apr 17, 2024 |
| CFRA | Cathy Seifert | $235 | $205.25 | -41.0% | Apr 17, 2024 |
| Morgan Stanley | Bob Huang | $214 | $206.06 | -46.3% | Apr 17, 2024 |
| UBS | Brian Meredith | $225 | $223.12 | -43.5% | Apr 17, 2024 |
| Raymond James | Gregory Peters | $185 | $159.68 | -53.6% | Jul 25, 2022 |
| RBC Capital | Mark Dwelle | $165 | $156.83 | -58.6% | Jul 22, 2022 |
| Wolfe Research | Charles Lederer | $156 | $163.15 | -60.8% | Jun 22, 2022 |
| Morgan Stanley | Analyst unavailable | $184 | $176.88 | -53.8% | Apr 20, 2022 |
| RBC Capital | Mark Dwelle | $190 | $184.86 | -52.3% | Apr 9, 2022 |
| Credit Suisse | Andrew Kligerman | $178 | $166.82 | -55.3% | Jan 30, 2022 |
| Jefferies | Yaron Kinar | $176 | $161.48 | -55.8% | Jan 6, 2022 |
| Bank of America Securities | Joshua Shanker | $152 | $156.96 | -61.8% | Oct 20, 2021 |
| UBS | Brian Meredith | $158 | $154.52 | -60.3% | Oct 11, 2021 |
Track every rating change on TRV the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationThe Travelers Companies, Inc., through its network of subsidiaries, delivers a broad spectrum of commercial and personal property and casualty insurance products and services. These offerings cater to businesses, government entities, associations, and individual clients both within the United States and internationally. The company's operations are divided into three primary segments: Business Insurance, Bond & Specialty Insurance, and Personal Insurance. The Business Insurance segment provides a comprehensive portfolio of commercial coverages, ranging from foundational offerings like workers' compensation, commercial auto, property, general liability, multi-peril, and employers' liability, to more specialized policies. These specialized offerings include public and product liability, professional indemnity, marine, aviation, onshore and offshore energy, construction, terrorism, personal accident, and even kidnap and ransom insurance.…
Historical context
All TRV earningsFinancial Services peers this season
Latest reports in the same sectorLatest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the TRV recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-10-17T05:10:49.140638+00:00
- Polygon adjusted daily market bars · 2026-10-24T14:50:44.009387+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T14:50:44.006292+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.